Skip to main content

Month: June 2020

Orphan Drugs Market to Surpass US$ 125,016.1 Mn by 2025, Pfizer’s Strong Distribution Network to Enable it Establish a Stronghold Worldwide, states Fortune Business Insights

Pune, June 03, 2020 (GLOBE NEWSWIRE) — The rising prevalence for chronic diseases is a major factor expected to drive the global orphan drugs market during the forecast period. Fortune Business Insights in a recent report, titled “Orphan Drugs Market Size, Share and Global Trend by Therapy Area (Oncology, Haematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy), Drug Type (Biologics, Non-Biologics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales) and Geography Forecast till 2025” published the above information. In the base year i.e. 2017, the global market was accounted for US$ 125,016.1 Mn and is estimated to reach US$ 294,037.8 Mn by forecast year i.e. 2025. Furthermore, the global market is anticipated to exhibit a CAGR of 11.4 % throughout the forecast years.The demand for oncology...

Continue reading

Providence Resources P.l.c. – 2019 Annual Results

Providence Resources P.l.c. – 2019 Annual ResultsDublin and London – June 3, 2020 – Providence Resources P.l.c. (PVR LN, PRP ID), the Irish based Energy company, today announces its Annual Results for the year ended December 31, 2019.FINANCIAL HIGHLIGHTSOperating loss for the period of €25.936 million versus €4.425 million in 2018Loss for the year of €26.853 million versus €4.779 million in 2018Loss per share of 4.39 cents versus 0.80 cents in 2018At 31 December 2019 total cash and cash equivalents were €0.710 million versus €7.617 million (at 31 December 2018)The Company had no debt at 31 December 2019The total issued and voting share capital comprises 835,397,852 ordinary shares of €0.001 each as at 2 June 20202019 REVIEWThe international operating environment for the oil and gas sector was relatively stable in 2019 with commodity...

Continue reading

Karolinska Development’s portfolio company Aprea Therapeutics completes enrollment in Phase 3 study of eprenetapopt

STOCKHOLM, SWEDEN – June 3, 2020. Karolinska Development AB’s (Nasdaq Stockholm: KDEV) portfolio company Aprea Therapeutics announced today that it has completed enrollment in a Phase 3 clinical trial evaluating eprenetapopt with azacitidine for the treatment of front-line TP53 mutant myelodysplastic syndromes (MDS). Topline results are expected by year-end 2020. Aprea plans to include the results of the trial in a New Drug Application (NDA) to the U.S. FDA and a Marketing Authorization Application (MAA) to the EMA in 2021.The randomized, controlled pivotal Phase 3 trial is designed to evaluate eprenetapopt with azacitidine compared with azacitidine alone as front-line therapy in intermediate, high, and very high risk TP53 mutant MDS patients. The multi-center trial enrolled 154 patients, randomized 1:1 to the two arms with a primary...

Continue reading

Karolinska Developments portföljbolag Aprea Therapeutics har slutfört rekryteringen av patienter till en fas 3-studie av eprenatapopt

STOCKHOLM, SVERIGE 3 juni 2020. Karolinska Development AB:s (Nasdaq Stockholm: KDEV) portföljbolag Aprea Therapeutics meddelade idag att man har slutfört rekryteringen i en fas 3-studie för utvärdering av läkemedelskandidaten eprenatapopt i kombination med azacitidine i patienter med TP53-muterat myelodysplastiskt syndrom (MDS). Topline-resultat förväntas kunna redovisas i slutet av 2020. Aprea planerar att inkludera studieresultaten i registreringsansökningar till den amerikanska läkemedelsmyndigheten FDA och dess europeiska motsvarighet EMA, vilka förväntas lämnas in under 2021.Den randomiserade, kontrollerade registreringsgrundande fas 3-studien är utformad för att utvärdera eprenetapopt i kombination med azacitidine, jämfört med azacitidine som monoterapi som en första linjens behandling för patienter med olika grad av muterat TP53...

Continue reading

INGENICO GROUP: PSD2 – Ingenico’s new SCA Accelerator Suite speeds up compliance

Ingenico’s new SCA Accelerator Suite speeds up complianceThe new authentication suite helps online businesses improve their performance and streamline the implementation of SCAIngenico Group (Euronext: FR0000125346 – ING), the global leader in seamless payments, today unveils its SCA accelerator suite to help online businesses remain compliant, innovate and better control their data. The suite will bring all of Ingenico ePayments’ expertise together to help online businesses improve their performance and facilitate the implementation of Strong Customer Authentication (SCA), due on 31 December 2020.The SCA Accelerator Suite from Ingenico utilizes the latest versions of 3D Secure, ensures businesses are compliant with The EU Second Payment Services Directive (PSD2), offers authentication routing, ensures the appropriate data collection...

Continue reading

INGENICO GROUP : DSP2 – Ingenico lance une nouvelle gamme pour accélérer la mise en conformité sur l’authentification forte du client (SCA)

DSP2 : Ingenico lance une nouvelle gamme pour accélérer la mise en conformité sur l’authentification forte du client (SCA)Cette nouvelle gamme d’authentification permettra aux acteurs en ligne d’améliorer leurs performances et de rationaliser la mise en œuvre de l’authentification forte du client (SCA)Ingenico Group (Euronext: FR0000125346 – ING), leader mondial des solutions de paiement intégrées lance aujourd’hui sa gamme SCA accelerator, pour aider les entreprises en ligne à rester conformes, à innover et à mieux contrôler leurs données. S’appuyant sur l’expertise d’Ingenico ePayments, elle permettra d’accompagner de la meilleure manière les entreprises en ligne, pour améliorer leurs performances et faciliter la mise en œuvre de la SCA, prévue au 31 décembre 2020.La gamme « SCA Accelerator » d’Ingenico...

Continue reading

Apple Rush Company, Inc. updates progress on Japan Distribution

TITUSVILLE, Fla., June 03, 2020 (GLOBE NEWSWIRE) — The Apple Rush Company, Inc. (US OTC PINK: APRU), updates its shareholders on our progress on Japanese distribution.The company has been working for several months on a distribution deal in Japan.  The process of gaining approval in Japan required very specific information in both formulation and processing of our flagship product. Quarantine in Japan (equivalent to our FDA) requires that all ingredient suppliers provide all of the components with percentages to them for safety verification and validation.  The information required was substantial and proprietary but the company was successful in gaining access to everything needed for the application.  “I am excited by the fact that we have been able to get through the next phase of the approval process.   Our partners provided...

Continue reading

Kintavar adds significant copper and mine development experience; nominates Guy Le Bel and Richard Faucher as Directors

MONTRÉAL, June 03, 2020 (GLOBE NEWSWIRE) — Kintavar Exploration Inc. (the “Corporation” or “Kintavar”) (TSX-V: KTR) (FRANKFURT: 58V), is very pleased to announce the nomination of Guy Le Bel and Richard R. Faucher as two new candidates for directorship. At the same time, Pierre Bertrand, who has been a director of Kintavar for 3 years, has resigned from its Board of Directors for personal reasons.The new directors will be proposed at Kintavar’s next Annual General Meeting (“AGM”). The AGM will take place on Monday, June 29th, 2020 at 10 a.m. (Eastern Time) at McMillan LLP 1000, Sherbrooke W, Suite 2700, Montréal, Québec.“First off, I would like to thank Pierre for his service and guidance that he provided to Kintavar since the early days of the Corporation. His knowledge and experience in the Quebec mining and exploration industry...

Continue reading

Kintavar ajoute de l’expérience significative dans le cuivre et le développement minier; nomme Guy Le Bel et Richard Faucher sur son conseil d’administration

MONTRÉAL, 03 juin 2020 (GLOBE NEWSWIRE) — Kintavar Exploration Inc. (la «Société» ou «Kintavar») (TSX-V: KTR) (FRANCFORT: 58V), est très heureuse d’annoncer la nomination de Guy Le Bel et Richard R. Faucher aux postes d’administrateurs. Dans le même temps, Pierre Bertrand, administrateur de Kintavar depuis 3 ans, démissionne de son poste sur le conseil d’administration pour des raisons personnelles.Les nouveaux administrateurs seront proposés à la prochaine assemblée générale annuelle («AGA») de Kintavar. L’AGA aura lieu le lundi 29 juin 2020 à 10 h (heure de l’Est) dans les locaux de McMillan LLP 1000, Sherbrooke Ouest, bureau 2700, Montréal (Québec).« Tout d’abord, je tiens à remercier Pierre pour ses services et ses conseils qu’il a fournis à Kintavar depuis les débuts de la Société. Ses connaissances...

Continue reading

Implementation of share capital reduction through cancellation of treasury shares; total number of shares and voting rights

On 21 August 2019, Bang & Olufsen A/S’ annual general meeting resolved to adopt a proposal by the Board of Directors to reduce the company’s share capital by nominally DKK 22,734,490 by cancellation of 2,273,449 treasury shares.In anticipation of the proposed rights issue described in company announcements 19.22, 19.23 and 20.02, the company has today resolved to complete the cancellation of the treasury shares. After the cancellation, the company’s share capital amounts to nominally DKK 409,240,290 divided into 40,924,029 shares each carrying 1 voting right, corresponding to a total of 40,924,029 voting rights, cf. section 32 of the Danish Capital Markets Act.The revised Articles of Association can be found on the company’s website, https://investor.bang-olufsen.com.In accordance with section 31 of the Danish Capital Markets Act,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.